Claro Advisors LLC Buys 2,509 Shares of Novo Nordisk A/S (NYSE:NVO)

Claro Advisors LLC lifted its stake in Novo Nordisk A/S (NYSE:NVO) by 10.6% in the 3rd quarter, Holdings Channel reports. The institutional investor owned 26,088 shares of the company’s stock after acquiring an additional 2,509 shares during the period. Claro Advisors LLC’s holdings in Novo Nordisk A/S were worth $3,106,000 as of its most recent filing with the SEC.

A number of other institutional investors have also added to or reduced their stakes in NVO. Advisor OS LLC lifted its holdings in Novo Nordisk A/S by 0.6% during the 2nd quarter. Advisor OS LLC now owns 13,972 shares of the company’s stock worth $1,994,000 after buying an additional 82 shares in the last quarter. Cascade Financial Partners LLC lifted its stake in shares of Novo Nordisk A/S by 2.3% during the second quarter. Cascade Financial Partners LLC now owns 3,801 shares of the company’s stock valued at $543,000 after acquiring an additional 84 shares during the period. Novare Capital Management LLC boosted its holdings in Novo Nordisk A/S by 3.2% in the third quarter. Novare Capital Management LLC now owns 2,727 shares of the company’s stock valued at $325,000 after acquiring an additional 85 shares during the last quarter. AA Financial Advisors LLC increased its position in Novo Nordisk A/S by 3.2% in the second quarter. AA Financial Advisors LLC now owns 2,805 shares of the company’s stock worth $400,000 after purchasing an additional 86 shares during the period. Finally, Steel Grove Capital Advisors LLC raised its holdings in Novo Nordisk A/S by 2.3% during the 2nd quarter. Steel Grove Capital Advisors LLC now owns 3,790 shares of the company’s stock worth $541,000 after purchasing an additional 86 shares during the last quarter. 11.54% of the stock is owned by institutional investors and hedge funds.

Novo Nordisk A/S Trading Down 3.4 %

NVO opened at $101.74 on Friday. Novo Nordisk A/S has a twelve month low of $94.73 and a twelve month high of $148.15. The firm has a market cap of $456.56 billion, a PE ratio of 32.93, a price-to-earnings-growth ratio of 1.31 and a beta of 0.42. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.75 and a current ratio of 0.94. The firm’s fifty day moving average is $118.58 and its two-hundred day moving average is $129.59.

Analyst Ratings Changes

Several research analysts have recently issued reports on NVO shares. StockNews.com raised shares of Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a research note on Friday, November 1st. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $160.00 target price on shares of Novo Nordisk A/S in a report on Wednesday, November 6th. Finally, BMO Capital Markets cut their price target on Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating on the stock in a research note on Thursday, October 17th. One research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $144.50.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.